Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Thyroid ; 18(4): 455-60, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18399769

ABSTRACT

OBJECTIVE: Recently it was found that thyrotropin (TSH) receptors are present both in osteoclast and osteoblast and that TSH can modulate bone remodeling independent of thyroid hormones. The aim of this study was, firstly, to evaluate the effects of acute administration of TSH on bone remodeling markers both in men and in women and, secondly, to evaluate if these effects are mediated by variations in serum osteoprotegerin (OPG) and receptor activator of nuclear factor-KB ligand (RANKL). DESIGN: We studied 30 thyroidectomized patients (10 premenopausal and 10 postmenopausal women, 10 men) affected by thyroid carcinoma on l-thyroxine therapy. Eighty age- and sex-matched subjects were used as controls. A blood sample was drawn from each patient at baseline and 3 and 5 days after recombinant human TSH (rhTSH) administration, in preparation for (131)I whole body scan, to assess serum bone markers and serum OPG and RANKL levels. MAIN OUTCOME: At baseline, postmenopausal women and men had significantly higher values of bone turnover markers and serum OPG compared to control subjects. In all thyroidectomized patients serum RANKL was lower than in controls. After rhTSH administration, serum N-terminal propeptide of type-I procollagen (PINP), a marker of bone formation, increased significantly in postmenopausal women, while serum RANKL significantly increased after 3 days in postmenopausal patients and men returning to baseline values at day 5. Serum OPG levels did not change significantly. CONCLUSIONS: The low serum TSH observed in thyroidectomized patients on l-thyroxine therapy is associated with an increase of bone turnover in postmenopausal women and men that is associated with an increase of OPG and a decrease of serum RANKL levels. The acute TSH administration results in an increase of PINP, an index of osteoblastic activity, associated with an increase of serum RANKL. The lack of this response in premenopausal women suggests an influence of estrogen status on bone reactivity to TSH.


Subject(s)
Bone and Bones/metabolism , Osteoprotegerin/blood , RANK Ligand/blood , Recombinant Proteins/therapeutic use , Thyroid Neoplasms/surgery , Thyrotropin/therapeutic use , Adult , Aged , Female , Humans , Male , Middle Aged , Thyroidectomy , Thyroxine/therapeutic use , Treatment Outcome
2.
Calcif Tissue Int ; 82(4): 258-62, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18418538

ABSTRACT

Nitrogen-containing bisphosphonates (N-BPs) inhibit osteoclast-mediated bone resorption and are widely used for tumor-associated osteolysis. The mechanism of action of these drugs has not been completely clarified, but it has been observed that N-BPs may inhibit squalene synthase or farnesyl pyrophosphate synthase. Zoledronic acid (ZA) represents a novel N-BP which also has antitumor activity. To explore the effects of ZA on serum lipids, we studied 26 patients with smoldering myeloma at diagnosis. Sixteen patients were treated with ZA (4 mg) at baseline and at months 1, 2, 4, and 6. The remaining 10 served as controls. In all subjects, total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and C-terminal telopeptide of type I collagen (CTX) were measured at baseline and after 1, 3, and 6 months. In treated patients, we observed a progressive and significant reduction of TC, with a maximum decrease of 13% at 6 months. Moreover LDL-C decreased by 21% at 6 months, while no significant difference was appreciated in HDL-C and TGs. Also, the indexes of cardiovascular risk improved after ZA administration: TC/HDL-C ratio progressively decreased by 17% and HDL-C/LDL-C ratio increased by 36%, showing an effect that appears to be cumulative. In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index.


Subject(s)
Diphosphonates/pharmacology , Imidazoles/pharmacology , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Aged , Aged, 80 and over , Atherosclerosis/metabolism , Bone Density Conservation Agents/therapeutic use , Cholesterol, HDL/metabolism , Collagen/chemistry , Diphosphonates/chemistry , Female , Humans , Lipids/chemistry , Male , Middle Aged , Treatment Outcome , Zoledronic Acid
3.
J Clin Densitom ; 7(3): 349-54, 2004.
Article in English | MEDLINE | ID: mdl-15319508

ABSTRACT

The aim of our study was to evaluate the reproducibility and the diagnostic accuracy of a new device for the assessment of bone mineral density (BMD) of the heel, called dual X-ray and laser (DXL Calscan). This technique associates X-ray absorptiometry to the measure of heel thickness with a laser beam. The calcaneus BMD, calcaneus quantitative sonography (QUS), and lumbar spine and total-body BMD, were evaluated in 40 postmenopausal women. On the basis of the BMD T-score measured by dual-energy X-ray absorptiometry (DXA) of L2-L4, 20 women were classified as osteoporotic and 20 women were considered nonosteoporotic according to the WHO classification. The short-term coefficient of variation of the DXL was 2.4% and 1.7% in osteoporotic and nonosteoporotic women, respectively. The calcaneus BMD was lower in osteoporotic than in nonosteoporotic women. Among osteoporotic patients, 14 patients had a T-score lower than -2.5 at Calscan, whereas only 4 patients classified as nonosteoporotic based on the lumbar spine BMD were misclassified by Calscan. In these patients, the sensitivity and specificity of heel ultrasound measurements were 70% and 85%, respectively. The DXL BMD was highly correlated with the total-body BMD, Stiffness at the calcaneus, and the L2-L4 BMD. In conclusion, the new measuring device the Calscan DXL appeared easy to use, the time of examination was relatively short, and the reproducibility was sufficiently good; the diagnostic accuracy and relationships with other devices were good.


Subject(s)
Absorptiometry, Photon/methods , Bone Density , Calcaneus/diagnostic imaging , Lasers , Aged , Female , Humans , Middle Aged , Osteoporosis/diagnosis , Reproducibility of Results
4.
Clin Orthop Relat Res ; (422): 208-13, 2004 May.
Article in English | MEDLINE | ID: mdl-15187859

ABSTRACT

Hypovitaminosis D is common in elderly women. Few data are available on vitamin D status and bone turnover in women with acute hip fracture. The aims of this study were to determine whether elderly Italian women with an acute hip fracture also had low vitamin D levels and an increase of bone turnover compared with elderly women with osteoporosis but without fractures. Seventy-four women with acute osteoporotic hip fracture and 73 women with postmenopausal osteoporosis were studied. All women were self-sufficient and had adequate sunlight exposure. To exclude the effect of trauma on serum 25-hydroxycolecalciferol levels and bone markers (bone alkaline phosphatase and C-terminal telopeptides of Type I collagen as indices of bone formation and bone resorption), blood samples were drawn within 24 hours of the fracture. Current data indicated that in our patients the prevalence of hypovitaminosis D is common although to a lesser extent than in women who are housebound. Women with acute hip fractures had a higher prevalence of vitamin deficiency defined as serum 25-hydroxycolecalciferol lower than 12 ng/mL, compared with women with osteoporosis. Moreover, the presence of fracture did not influence the rate of bone formation, whereas the increase in bone resorption could be attributed to an older age of women with acute hip fracture because of similar values of parathyroid hormone levels in the two groups.


Subject(s)
Bone Resorption/physiopathology , Hip Fractures/diagnosis , Osteoporosis, Postmenopausal/diagnosis , Vitamin D Deficiency/diagnosis , Vitamin D/metabolism , Age Distribution , Aged , Aged, 80 and over , Analysis of Variance , Biomarkers/analysis , Bone Density , Case-Control Studies , Cohort Studies , Densitometry , Female , Follow-Up Studies , Hip Fractures/epidemiology , Hip Fractures/etiology , Humans , Incidence , Osteoporosis, Postmenopausal/blood , Osteoporosis, Postmenopausal/epidemiology , Probability , Reference Values , Risk Assessment , Vitamin D/analysis , Vitamin D Deficiency/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...